Biocon Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Biocon Ltd filed with BSE on 14 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Biocon reported Q4 FY26 group operating revenue growth of 10% year-on-year excluding the prior-year lenalidomide bonus, with biosimilars growing 12%, generics excluding lenalidomide growing 13%, and CRDMO growing 2%. EBITDA came in at Rs 1,073 crore with a 23% margin, up 29% year-on-year on an adjusted basis, and reported net profit before exceptionals was Rs 179 crore. Management described completion of the Biocon Biologics minority buyout and integration of the biosimilars and generics businesses, and said interest cost savings from refinancing have begun accruing with full annualized benefit expected from FY27.
Numbers mentioned
Operating revenue growth: 10% year-on-year (Q4 FY26)
p. 5
“the group delivered a biosimilars-led 10% year-on-year growth in operating revenue, excluding the onetime bonus of generic lenalidomide in Q4 FY '25”
Kiran Mazumdar Shaw, page 5 of the filed PDF · View the filing
EBITDA: INR1,073 crores (Q4 FY26)
p. 6
“EBITDA was at INR1,073 crores with a margin of 23%.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Net profit before exceptionals: INR179 crores (Q4 FY26)
p. 6
“The reported net profit for the quarter before exceptionals was INR179 crores.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Biosimilars revenue: ₹2,756 crores (Q4 FY26)
p. 7
“Biosimilars revenue for Q4 FY '26 stood at ₹2,756 crores, representing a 12% year-on-year increase, driven primarily by advanced markets.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Biosimilars EBITDA margin: 26% (Q4 FY26)
p. 7
“This translates into an EBITDA margin of 26%.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Generics revenue: ₹847 crores (Q4 FY26)
p. 7
“Revenue stood at ₹847 crores and adjusted for the one-time generic lenalidomide supplies in Q4 of FY '25, revenues grew 13% year-on-year, driven by generic liraglutide sales in Europe.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Generics EBITDA margin: 8% (Q4 FY26)
p. 7
“EBITDA stood at ₹75 crores. EBITDA margins were at 8%, improved nearly 300 basis points over Q3 of this fiscal, driven by higher volumes and operating leverage.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
CRDMO revenue: ₹1,037 crores (Q4 FY26)
p. 7
“In Q4 FY '26, revenues from operations were at ₹1,037 crores, up 2% year-on-year and up 13% quarteron-quarter.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Net debt: $1.1 billion (current)
p. 10
“That's down to $1.1 billion now.”
Kedar Upadhye, page 10 of the filed PDF · View the filing
Insulin franchise revenue: beyond $300 million (FY26)
p. 13
“Insulin now has crossed $300 million this year.”
Kedar Upadhye, page 13 of the filed PDF · View the filing
Adalimumab revenue: beyond $250 million (FY26)
p. 14
“Adalimumab is now beyond $250 million and Pegfilgrastim, Trastuzumab are hovering around $200 million or slightly lower than that.”
Kedar Upadhye, page 14 of the filed PDF · View the filing
Bevacizumab revenue: crossed $100 million (FY26)
p. 14
“Bevacizumab has crossed $100 million now.”
Kedar Upadhye, page 14 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Interest cost savings — full annualized benefit · FY27
stated firmly by Kiran Mazumdar Shaw
p. 5
“Importantly, interest cost savings have begun to accrue, and the full annualized benefit will be visible from FY '27, further supporting profitability and cash generation.”
Kiran Mazumdar Shaw, page 5 of the filed PDF · View the filing
Biosimilars growth and product ramp-up — second half of FY27
stated conditionally by Kedar Upadhye
p. 15
“we don't guide specifically Tushar, but like what Shreehas said, you should budget for incremental growth from new launches more towards second half.”
Kedar Upadhye, page 15 of the filed PDF · View the filing
Malaysia drug substance capacity doubling — doubling of drug substance capacity · end of FY27
stated firmly by Kedar Upadhye
p. 15
“DS, the drug substance doubling will happen towards the end of this financial year.”
Kedar Upadhye, page 15 of the filed PDF · View the filing
Capex — FY27
stated firmly by Shreehas Tambe
p. 20
“Yes. We've already said that.”
Shreehas Tambe, page 20 of the filed PDF · View the filing
Net debt range — $1.1 billion to $1.2 billion
stated conditionally by Kedar Upadhye
p. 10
“So, it will hover between $1.1 billion to $1.2 billion subject to working capital.”
Kedar Upadhye, page 10 of the filed PDF · View the filing
Generics margin improvement — coming quarters
stated as an aspiration by Shreehas Tambe
p. 16
“The focus for us going forward is very clearly going to be on margin improvement because we built state-of-the-art facilities.”
Shreehas Tambe, page 16 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management pointed to sequential quarter-on-quarter revenue growth and said ramp-up from new launches would build through FY27/FY28, especially in the second half.
Answered by Shreehas Tambe
Asked by Neha Manpuria: Whether biosimilars disruption from the Q3 planned shutdown has fully stabilized and how to think about FY27/FY28 growth.
p. 8
“if you look at the numbers between Q3 and Q4, you have seen a sequential change, where we moved from a quarter which was $279 million, $280 million to about $300-plus million this quarter.”
Shreehas Tambe, page 8 of the filed PDF · View the filing
Kedar confirmed free cash flow generated will primarily go toward debt reduction, with net debt down from $1.5 billion to $1.1 billion.
Answered by Kedar Upadhye
Asked by Neha Manpuria: How should deleveraging be thought about in FY27 post the Biocon Biologics merger.
p. 10
“every dollar that we generate out of free cash, the first claim is going to be to reduce debt, and we are pretty serious about it.”
Kedar Upadhye, page 10 of the filed PDF · View the filing
Management gave a roughly 75%-25% advanced-to-emerging market split and described plans to launch Yesafili (aflibercept) and Kirsty (Aspart) in the second half of FY27.
Answered by Shreehas Tambe
Asked by Damayanti Kerai: Split of FY26 biosimilars sales between developed and emerging markets, and outlook for aflibercept and Aspart.
p. 10
“roughly 75%-25% if you're asking advanced markets and emerging markets, could be between 78%, 22% in a particular quarter, but that's the broad split.”
Shreehas Tambe, page 10 of the filed PDF · View the filing
Kedar said dollar growth is roughly 3-4 points lower than rupee growth, and listed insulin, adalimumab, pegfilgrastim, trastuzumab and bevacizumab progress against the $200 million benchmark.
Answered by Kedar Upadhye
Asked by Sidharth Negandhi: Constant currency growth by division and update on products above $200 million.
p. 13
“Insulin now has crossed $300 million this year. So that's the bracket that it has crossed and that includes Glargine, Aspart, human insulin, DS and DP.”
Kedar Upadhye, page 13 of the filed PDF · View the filing
Management said the change lowers development cost and timeline for new entrants but raises analytical comparability requirements, favoring companies like Biocon with strong CMC track records, and does not see incremental challenge for its marketed products.
Answered by Shreehas Tambe
Asked by Avnish Burman: Impact of FDA draft guidelines reducing R&D cost for new biosimilars on Biocon's existing and pipeline products.
p. 12
“it has reduced the development cost by 50%. It's half the development cost. And it's accelerated products from a development standpoint by at least 3 to 4 years”
Shreehas Tambe, page 12 of the filed PDF · View the filing
Kedar said utilization is healthy, Malaysia capacity is doubling for drug substance and drug product, and no large greenfield capex is currently needed.
Answered by Kedar Upadhye
Asked by Tushar Manudhane: Current biosimilars capacity utilization and whether further capacity expansion is needed for FY27/28 growth.
p. 15
“as of now, we don't see any need for a large greenfield capex, Tushar.”
Kedar Upadhye, page 15 of the filed PDF · View the filing
Kedar confirmed North America is currently around 46% of biosimilars this quarter, gave global product-level revenue figures, and said erosion should be expected though it varies by product.
Answered by Kedar Upadhye
Asked by Vishal Manchanda: Breakdown of biosimilar sales by geography and largest product, and base business price erosion.
p. 20
“Within the biosimilars, NorAm led by U.S. is about 46% this quarter.”
Kedar Upadhye, page 20 of the filed PDF · View the filing
Shreehas estimated the overall insulin market at $7-8 billion and said Chinese entrants validate the attractiveness of the market rather than posing an immediate threat given the scale and integration required to compete.
Answered by Shreehas Tambe
Asked by Nitin Agarwal: Size of the global addressable insulin market and risk from recent Chinese company approvals.
p. 21
“it will be around at $7 billion, $8 billion overall insulin.”
Shreehas Tambe, page 21 of the filed PDF · View the filing
Risks flagged
Geopolitical uncertainty affecting supply chains, logistics and energy costs
p. 4
“The external environment remained challenging throughout the quarter with geopolitical uncertainty continuing to impact supply chains, logistics and energy costs.”
Kiran Mazumdar Shaw, page 4 of the filed PDF · View the filing
CRDMO business impacted by a single large biologics client
p. 7
“Overall numbers reflected the specific impact from a single large molecule biologics client with the underlying business showing steady momentum.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Expected price erosion in the base biosimilars portfolio
p. 20
“But yes, I think we should budget for some erosion, Vishal.”
Kedar Upadhye, page 20 of the filed PDF · View the filing
Declining average selling price dynamic in medical benefit biosimilars affecting market share strategy
p. 18
“market share and ASP has always been inversely proportional in a medical benefit product.”
Shreehas Tambe, page 18 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.